1. Armah B.I. (1987): Contributions of presynaptic α2-adrenoceptor stimulation to the antihypertensive action of moxonidine. J. Cardiovasc. Pharmacol., 10 (Suppl. 4), 81–83.
2. Armah B.I., Hofferber E., Stenzel W. (1988): General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittelforsch., 38 (II), 10, 1426–1434.
3. Bergerhausen J. (1985): Moxonidine (BE S89S), a novel full agonist at human platelet alpha-2-adrenoceptors. Naunyn-Schmiedeberg Arch. Pharmacol., 329, R80.
4. Kukovetz W.R., Diembeck W. (1986): Pharmacokinetic study after intravenous and oral administration of11C-moxonidine to humans. Unpublished observations.
5. Trenk D., Wagner F., Jähnchen E., Planitz V. (1987): Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J. Clin. Pharmacol., 27, 988–993.